During the past decade, Hebei Petro China Central Hospital conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Hebei Petro China Central Hospital" are "Alzheimer Disease" (1 trials) and "Colorectal Cancer" (1 trials). Many other conditions were trialed in "Hebei Petro China Central Hospital" in a lesser frequency.

Most popular intervention types in "Hebei Petro China Central Hospital" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Anlotinib" (1 trials), "Penpulimab" (1 trials) and "Sodium Oligomannate Capsules" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hebei Petro China Central Hospital" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Hebei Petro China Central Hospital". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Hebei Petro China Central Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Hebei Petro China Central Hospital, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".